- Price
- $9.52
- Day
- +7.69%
- Mkt Cap
- $283.58M
- 52W Range
- $2.57 – $26.50
- Volume
- 44.8K
- Beta
- 2.10
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced that Bradley Burnam, Founder and Chief Executive Officer, will ring the Nasdaq Closing Bell on August 10, 2026, along with members of the Turn Therapeutics management team, at Nasdaq's invitation to mark its progress to date. "We're honored that Nasdaq invited us back to share our stor.
Read full article
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today
Read full article